Amplification of probiotic bacteria in the skin microbiome to combat Staphylococcus aureus infection
Tristan Yusho Huang A B , Deron Raymond Herr C , Chun-Ming Huang A D and Yong Jiang E F
+ Author Affiliations
- Author Affiliations
A Department of Dermatology, School of Medicine, University of California, San Diego, CA 92093, USA
B Canyon Crest Academy, San Diego, CA 92130, USA
C Department of Pharmacology, National University of Singapore, 117600, Singapore
D Department of Biomedical Sciences and Engineering, National Central University, Taoyuan, 32001, Taiwan
E America Diagnosis, Inc., San Diego, CA 92121, USA
F Tel.: +858-207-6226, Email: yJiang@ameridx.com
Microbiology Australia 41(2) 61-64 https://doi.org/10.1071/MA20018
Published: 5 May 2020
Abstract
Staphylococcus aureus (S. aureus) is a Gram-positive bacterium. When pathogenic S. aureus colonises onto a skin wound or diabetic ulcer, it can cause a serious infection and lead to amputation or death. The current solutions (e.g. antibiotics and probiotics) are not sufficient enough to be a cure for this infection. To worsen the situation, the S. aureus bacteria continue to develop greater resistance towards antibiotics and are becoming more commonplace. An effective solution is to amplify the activity of probiotic bacteria in the skin microbiome by using selective fermentation initiators (SFIs) to induce fermentation. Our data demonstrated that the numbers of Cutibacterium acnes (C. acnes) and Staphylococcus epidermidis (S. epidermidis), two major bacteria in skin microbiome, on human skin did not vary significantly over the span of seven days. This stimulates probiotic bacteria such as S. epidermidis to produce sufficient short-chain fatty acids (SCFAs) to suppress the growth of S. aureus. The development of this new cure to S. aureus may reduce hospitalisation greatly as S. aureus accounts for the hospitalisation of more than five thousand people per year. Besides antibiotic, probiotics and bacteriophages, SFIs may become novel agents for treatment of infection.
References
[1] Chen, Y.E. et al. (2018) Skin microbiota-host interactions. Nature 553, 427–436.| Skin microbiota-host interactions.Crossref | GoogleScholarGoogle Scholar | 29364286PubMed |
[2] Kaur, N. et al. (2011) Intestinal dysbiosis in inflammatory bowel disease. Gut Microbes 2, 211–216.
| Intestinal dysbiosis in inflammatory bowel disease.Crossref | GoogleScholarGoogle Scholar | 21983063PubMed |
[3] Grice, E.A. et al. (2012) The human microbiome: our second genome. Annu. Rev. Genomics Hum. Genet. 13, 151–170.
| The human microbiome: our second genome.Crossref | GoogleScholarGoogle Scholar | 22703178PubMed |
[4] Ren, T. et al. (2013) 16S rRNA survey revealed complex bacterial communities and evidence of bacterial interference on human adenoids. Environ. Microbiol. 15, 535–547.
| 16S rRNA survey revealed complex bacterial communities and evidence of bacterial interference on human adenoids.Crossref | GoogleScholarGoogle Scholar | 23113966PubMed |
[5] Iwase, T. et al. (2010) Staphylococcus epidermidis Esp inhibits Staphylococcus aureus biofilm formation and nasal colonization. Nature 465, 346–349.
| Staphylococcus epidermidis Esp inhibits Staphylococcus aureus biofilm formation and nasal colonization.Crossref | GoogleScholarGoogle Scholar | 20485435PubMed |
[6] Naik, S. et al. (2012) Compartmentalized control of skin immunity by resident commensals. Science 337, 1115–1119.
| Compartmentalized control of skin immunity by resident commensals.Crossref | GoogleScholarGoogle Scholar | 22837383PubMed |
[7] Grice, E.A. et al. (2011) The skin microbiome. Nat. Rev. Microbiol. 9, 244–253.
| The skin microbiome.Crossref | GoogleScholarGoogle Scholar | 21407241PubMed |
[8] Ahn, C. et al. (1996) Microbial evaluation: 139 implants removed from symptomatic patients. Plast. Reconstr. Surg. 98, 1225–1229.
| Microbial evaluation: 139 implants removed from symptomatic patients.Crossref | GoogleScholarGoogle Scholar | 8942908PubMed |
[9] Cogen, A.L. et al. (2008) Skin microbiota: a source of disease or defence? Br. J. Dermatol. 158, 442–455.
| Skin microbiota: a source of disease or defence?Crossref | GoogleScholarGoogle Scholar | 18275522PubMed |
[10] Fluhr, J.W. et al. (2008) Glycerol and the skin: holistic approach to its origin and functions. Br. J. Dermatol. 159, 23–34.
| Glycerol and the skin: holistic approach to its origin and functions.Crossref | GoogleScholarGoogle Scholar | 18510666PubMed |
[11] Ushijima, T. et al. (1984) Acetic, propionic, and oleic acid as the possible factors influencing the predominant residence of some species of Propionibacterium and coagulase-negative Staphylococcus on normal human skin. Can. J. Microbiol. 30, 647–652.
| Acetic, propionic, and oleic acid as the possible factors influencing the predominant residence of some species of Propionibacterium and coagulase-negative Staphylococcus on normal human skin.Crossref | GoogleScholarGoogle Scholar | 6744125PubMed |
[12] Ryssel, H. et al. (2009) The antimicrobial effect of acetic acid--an alternative to common local antiseptics? Burns 35, 695–700.
| The antimicrobial effect of acetic acid--an alternative to common local antiseptics?Crossref | GoogleScholarGoogle Scholar | 19286325PubMed |
[13] Sebastian, S. et al. (1996) Comparative assessment of bacterial inoculation and propionic acid treatment of aerobic stability and microbial populations of ensiled high-moisture ear corn. J. Anim. Sci. 74, 447–456.
| Comparative assessment of bacterial inoculation and propionic acid treatment of aerobic stability and microbial populations of ensiled high-moisture ear corn.Crossref | GoogleScholarGoogle Scholar | 8690682PubMed |
[14] Tong, X. et al. (2004) Butyrate suppresses Cox-2 activation in colon cancer cells through HDAC inhibition. Biochem. Biophys. Res. Commun. 317, 463–471.
| Butyrate suppresses Cox-2 activation in colon cancer cells through HDAC inhibition.Crossref | GoogleScholarGoogle Scholar | 15063780PubMed |
[15] Hassan, M.A. et al. (2019) Insight into multidrug-resistant microorganisms from microbial infected diabetic foot ulcers. Diabetes Metab. Syndr. 13, 1261–1270.
| Insight into multidrug-resistant microorganisms from microbial infected diabetic foot ulcers.Crossref | GoogleScholarGoogle Scholar | 31336475PubMed |
[16] Norouzi, H. et al. (2018) Marine actinomycetes with probiotic potential and bioactivity against multidrug-resistant bacteria. Int. J. Mol. Cell. Med. 7, 44–52.
| Marine actinomycetes with probiotic potential and bioactivity against multidrug-resistant bacteria.Crossref | GoogleScholarGoogle Scholar | 30234072PubMed |
[17] Prazak, J. et al. (2019) Bacteriophages improve outcomes in experimental Staphylococcus aureus ventilator associated pneumonia. Am. J. Respir. Crit. Care Med. 200, 1126–1133.
| Bacteriophages improve outcomes in experimental Staphylococcus aureus ventilator associated pneumonia.Crossref | GoogleScholarGoogle Scholar | 31260638PubMed |
[18] Carlton, R.M. (1999) Phage therapy: past history and future prospects. Arch. Immunol. Ther. Exp. (Warsz.) 47, 267–274.
| 10604231PubMed |
[19] Ding, Y. et al. (2019) In vitro digestion under simulated saliva, gastric and small intestinal conditions and fermentation by human gut microbiota of polysaccharides from the fruits of Lycium barbarum. Int. J. Biol. Macromol. 125, 751–760.
| In vitro digestion under simulated saliva, gastric and small intestinal conditions and fermentation by human gut microbiota of polysaccharides from the fruits of Lycium barbarum.Crossref | GoogleScholarGoogle Scholar | 30552927PubMed |
[20] Tsitko, I. et al. (2019) A small in vitro fermentation model for screening the gut microbiota effects of different fiber preparations. Int. J. Mol. Sci. 20, 1925.
| A small in vitro fermentation model for screening the gut microbiota effects of different fiber preparations.Crossref | GoogleScholarGoogle Scholar |
[21] Barbirato, F. et al. (1997) Propionic acid fermentation from glycerol: comparison with conventional substrates. Appl. Microbiol. Biotechnol. 47, 441–446.
| Propionic acid fermentation from glycerol: comparison with conventional substrates.Crossref | GoogleScholarGoogle Scholar |
[22] Robbins, G.B. et al. (1940) Fermentation of sugar acids by bacteria. J. Bacteriol. 39, 399–404.
| Fermentation of sugar acids by bacteria.Crossref | GoogleScholarGoogle Scholar | 16560301PubMed |
[23] Safonova, T.B. et al. (1978) Importance of carbohydrate tests for interspecies differentiation of staphylococci. Zh. Mikrobiol. Epidemiol. Immunobiol. 9, 98–101.
[24] Louie, T.J. et al. (1976) Aerobic and anaerobic bacteria in diabetic foot ulcers. Ann. Intern. Med. 85, 461–463.
| Aerobic and anaerobic bacteria in diabetic foot ulcers.Crossref | GoogleScholarGoogle Scholar | 970773PubMed |
[25] Dowd, S.E. (2008) Polymicrobial nature of chronic diabetic foot ulcer biofilm infections determined using bacterial tag encoded FLX amplicon pyrosequencing (bTEFAP). PLoS One 3, e3326.
| Polymicrobial nature of chronic diabetic foot ulcer biofilm infections determined using bacterial tag encoded FLX amplicon pyrosequencing (bTEFAP).Crossref | GoogleScholarGoogle Scholar | 18833331PubMed |
[26] Kao, M.S. et al. (2017) Microbiome precision editing: using PEG as a selective fermentation initiator against methicillin-resistant Staphylococcus aureus. Biotechnol. J. 12, .
| Microbiome precision editing: using PEG as a selective fermentation initiator against methicillin-resistant Staphylococcus aureus.Crossref | GoogleScholarGoogle Scholar | 27982519PubMed |
[27] Wang, Y. et al. (2016) A precision microbiome approach using sucrose for selective augmentation of Staphylococcus epidermidis fermentation against Propionibacterium acnes. Int. J. Mol. Sci. 17, 1870.
| A precision microbiome approach using sucrose for selective augmentation of Staphylococcus epidermidis fermentation against Propionibacterium acnes.Crossref | GoogleScholarGoogle Scholar |
